Disease · MONDO_0004647
Trials23
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 20 of 23
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04165317 | A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer | Phase 3 | 1,068 | 2026-01-22 | Non-muscle Invasive Bladder Cancer | BCG VACCINE, SASANLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02773849 | ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 3 | 157 | 2022-07-13 | Superficial Bladder Cancer | NADOFARAGENE FIRADENOVEC | Its record names the disease | ClinicalTrials.gov |
| NCT02449239 | Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG | Phase 3 | 133 | 2023-07-24 | Bladder Cancer | OPORTUZUMAB MONATOX | Its record names the disease | ClinicalTrials.gov |
| NCT00453336 | Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract | Phase 2 | 45 | 2013-10-18 | Head and Neck Cancer, Precancerous/Nonmalignant Condition | PORFIMER SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT00530088 | Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat | Not applicable | 30 | 2014-07-04 | Head and Neck Cancer | PORFIMER SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT03258593 | Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) | Phase 1 | 15 | 2023-10-26 | Urinary Bladder Neoplasms | DURVALUMAB, OPORTUZUMAB MONATOX | Its record names the disease | ClinicalTrials.gov |
| NCT05714202 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) | Phase 3 | 1,135 | Bladder Cancer | CETRELIMAB, GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07000084 | Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy | Phase 3 | 330 | Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8 | GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06545955 | A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | 250 | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | DOCETAXEL, GEMCITABINE, NADOFARAGENE FIRADENOVEC, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04640623 | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | Phase 2 | 220 | Urinary Bladder Neoplasms | CETRELIMAB, GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04452591 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Phase 3 | 190 | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | CRETOSTIMOGENE GRENADENOREPVEC | Its record names the disease | ClinicalTrials.gov | |
| NCT07189793 | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study | Phase 2 | 106 | Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder, Non-Muscle-Invasive Bladder Cancer | GEMCITABINE, MITOMYCIN, TORIPALIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00281736 | Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer | Phase 2 | 60 | Esophageal Cancer, Precancerous Condition | HPPH | Its record names the disease | ClinicalTrials.gov | |
| NCT04311580 | Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure | Phase 2 | 52 | Bladder Cancer | BCG VACCINE, MITOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05893888 | A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers | Phase 2/3 | 40 | Oral Squamous Cell Carcinoma | CISPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04387461 | Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin | Phase 2 | 35 | Non Muscle Invasive Bladder Cancer | CRETOSTIMOGENE GRENADENOREPVEC, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00675233 | Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx | Phase 1 | 29 | Head and Neck Cancer | HPPH | Its record names the disease | ClinicalTrials.gov | |
| NCT01238042 | Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus | Phase 1 | 18 | Barrett's Esophagus, CIS, HGD | HPPH | Its record names the disease | ClinicalTrials.gov | |
| NCT07283835 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Phase 2 | 16 | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | CRETOSTIMOGENE GRENADENOREPVEC | Its record names the disease | ClinicalTrials.gov | |
| NCT00670397 | Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer | Phase 1 | 11 | Head and Neck Cancer | HPPH | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004647/trials